Abbvie Inc.

Pfizer Corporation

Abbott Laboratories Corporation

Pharmacia & Upjohn Company

Other

Pharmacia & Upjohn

Abbyie Inc.

Kristine E Frank

Michael D Ennis

Jian-Min Fu

Michael M Friedman

David J Calderwood

Robert Louis Hoffman

Neil Wishart

Patrick Robert Verhoest

Eric Jon Jacobsen

Brad A Acker

Jeffrey W Corbett

Lu Wang

Maria A Argiriadi

Biqin C Li

Dawn M George

Grier A Wallace

Anna M Ericsson

Anil Vasudevan

Kent D Stewart

Donald J Rogier

Michael Z Hoemann

William W McWhorter, Jr

Eric C Breinlinger

Noel S Wilson

Augustine Osuma

Kevin R Woller

Michael Morytko

Jackson B Hester, Jr

Bruce Nelsen Rogers

Kenton L Longenecker

Richard W Dixon

David Wayne Borhani

Justin D Dietrich

Jeffrey W Voss

Stevan Wakefield Djuric

Marlon D Cowart

Arthur Gomtsyan

Michael L Friedman

Nathan Josephsohn

Jed F Fisher

Jeanette Kay Morris

Kelly Mullen

Heather M Davis

J Martin Herold

Eric R Goedken

Xiangdong Xu

Kevin Patrick Cusack

Andrew Burchat

Dominique Bonafoux

Phil B Cox

Gagandeep K Somal

Ann Marie Rowley

Stacy A Van Epps

Susan L Vander Velde

Raymond Huntley

Bryan A Fiamengo

Huan-Qui Li

Michael R Schrimpf

George S Sheppard

Jerome F Daanen

Gavin C Hirst

Mikhail A Chafeev

Thomas D Gordon

Huaqing Liu

Robert G Schmidt

Michael L Curtin

Marc J Scanio

Robert V Talanian

Zhi Wang

Xiaoyun Wu

Patrick Betschmann

Tatyana Dekhtyar

Ping Ding

Claude E Barberis

Iok Chan Ng

M-akhteruzzaman Molla

Artour Gomtsian

Matthew H Katcher

Philip Cox

Jennifer Van Camp

Nathan S Josephsohn

Amanda W Dombrowski

Lily K Abbott

Xiaolei Zhang

Barbara S Skinner

Thomas R Vargo

Eric C Brieinlinger

Matthew P Webster

Andrew J Little

Mikhail Chafeev

Ellen Yulin Tsai Chien

David J Hardee

Wei Qiu

Michael J Morytko

Biqin Li

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R2, R, R, R, X, X, X, X, X, nad n are as defined herein, pharmaeceutical compositions 2C X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 

Inhibitors of tyrosine kinase 2 mediated signaling

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. 

Heterocyclic kinase inhibitors

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Tricyclic modulators of TNF signaling

The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Tricyclic compounds

This disclosure relates to: (a) compounds and salts of formula (I), formula (II), formula (III), and formula (IV), that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 

Substituted cyanoguanidines as oral anti-virals

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Primary carboxamides as BTK inhibitors

The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

The invention provides a compound of Formula (Ie), 

Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof

The present disclosure is directed to novel compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Crohn's disease, psoriasis and asthma.

[object Object]

The present invention is directed to novel compounds of formula (I) wherein the variables are defined as herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Triazolopyridazines

Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Indazole compounds

The present invention is directed to novel compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Imidazothiazoles and imidazoxazoles

Growing community of inventors

Grayslake, IL, United States of America

Kristine E Frank